BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2227836)

  • 1. Combined immunohistochemical study of tissue polypeptide antigen and cancer antigen 125 in human ovarian tumours.
    Ghazizadeh M; Sasaki Y; Oguro T; Aihara K; Tenjin H; Araki T
    Histopathology; 1990 Aug; 17(2):123-8. PubMed ID: 2227836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical and ultrastructural localization of tissue polypeptide antigen in human ovarian tumours.
    Ghazizadeh M
    Virchows Arch A Pathol Anat Histopathol; 1989; 414(5):453-7. PubMed ID: 2499102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Distribution and diagnostic role of COTA in mucinous ovarian tumors].
    Shi ZL
    Zhonghua Zhong Liu Za Zhi; 1989 May; 11(3):191-2. PubMed ID: 2612330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
    Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y
    Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour-associated antigen CA 125 in patients with ovarian cancer.
    Heinonen PK; Tontti K; Koivula T; Pystynen P
    Br J Obstet Gynaecol; 1985 May; 92(5):528-31. PubMed ID: 3857939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen.
    Imai S; Kiyozuka Y; Maeda H; Noda T; Hosick HL
    Oncology; 1990; 47(2):177-84. PubMed ID: 2314830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
    Fukazawa I; Inaba N; Ota Y; Sato N; Shirotake S; Iwasawa H; Sekiya S; Takamizawa H; Suzuki N; Tokita H
    Arch Gynecol Obstet; 1988; 243(2):69-81. PubMed ID: 3165255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative measurement of ovarian carcinoma antigen and carcinoembryonic antigen in the serum of ovarian cancer.
    Yuan CC; Ng HT; Tsai LC; Jeng FS; Yeh SH; Tsai YC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1987 Aug; 20(3):190-7. PubMed ID: 3480793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of CEA, CA125, CA19-9 and human milk fat globule membrane antigen in ovarian tumours.
    Macdonald F; Bird R; Stokes H; Russell B; Crocker J
    J Clin Pathol; 1988 Mar; 41(3):260-4. PubMed ID: 3162916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA-125, placental alkaline phosphatase and tissue polypeptide antigen as preoperative serum markers in ovarian carcinoma.
    Toftager-Larsen K; Hørding U; Dreisler A; Daugaard S; Lund B; Bock J; Lundvall F; Frederiksen K; Nørgaard-Pedersen B
    Gynecol Obstet Invest; 1992; 33(3):177-82. PubMed ID: 1319386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) and their immunohistochemical identification in benign and malignant gynecological disease.
    Fukazawa I; Inaba N; Ota Y; Sato N; Shirotake S; Iwasawa H; Sato T; Takamizawa H; Wiklund B
    Arch Gynecol Obstet; 1988; 243(1):41-50. PubMed ID: 3165614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
    Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
    Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
    Kataoka A; Yakushiji M
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
    Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
    Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue polypeptide antigen in thyroid tumours of follicular cell origin: an immunohistochemical re-evaluation for diagnostic purposes.
    Tuccari G; Barresi G
    Histopathology; 1990 Apr; 16(4):377-81. PubMed ID: 2361653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies that discriminate between human ovarian carcinomas and benign ovarian tumours.
    Boerman OC; Makkink WK; Thomas CM; Hanselaar AG; Yedema CA; Kenemans P; Poels LG
    Eur J Cancer; 1990 Feb; 26(2):117-27. PubMed ID: 2138906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers.
    Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M
    Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placental alkaline phosphatase (PLAP)/PLAP-like alkaline phosphatase as tumour marker in relation to CA 125 and TPA for ovarian epithelial tumours.
    Stigbrand T; Riklund K; Tholander B; Hirano K; Lalos O; Stendahl U
    Eur J Gynaecol Oncol; 1990; 11(5):351-60. PubMed ID: 2097151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
    Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y
    Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
    Mogensen O; Mogensen B; Jakobsen A
    Br J Cancer; 1990 Feb; 61(2):327-9. PubMed ID: 2310684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.